Abstract:Abstract The role of tumor microenvironment during the initiation and progression of breast cancer is now realized to be of critical importance, both for understanding of the fundamental cancer biology and exploiting relatively new mechanism for breast cancer metastasis. Macrophage is a one of the most common components in the breast cancer microenvironment. Normally, the macrophage in tumor microenvironment is referred to tumor associated macrophage (TAM), which shares some attributes of alternatively activated macrophage. Many pre-clinical and clinical studies demonstrate an inverse correlation between TAM infiltration and patients' prognosis indicating a macrophage supporting role for tumor progression. It is well documented that selective patients with breast cancer can benefit from anti-estrogen therapy. However, the mechanisms involved are still not fully elucidated. Our previous study indicates that highly tumorigenic breast cancer cell line MDA-MB-231 can educate monocyte differentiation into alternatively activated macrophage, while weakly tumorigenic cell line MCF-7 (without estrogen supplementation) can not. In the present study, we explored the effects of estrogen and tamoxifen on the secreting of certain cytokines, which are required for monocyte chemotaxis and differentiation. Breast cancer cell lines with different estrogen receptor status were applied to estimate the level of cytokines (IL4, IL6, M-CSF, GM-CSF, and MCP-1) before and after cultured with 17β-estradiol, tamoxifen or both. We found that weakly invasive breast cancer cell lines (MCF-7, T47D, MDA-MB-468, and SKBR3) generally expressed lower levels of such cytokines compared with highly invasive breast cancer cell lines (MDA-MB-231, MDA-MB-231-BO, MDA-MB-231 HM, Bcap 37, BT549, and Hs578T) at baseline. However, the discrepancies could be compensated partially by exposure to 10nM 17β-estradiol in estrogen receptor (ER) positive cell lines (MCF-7 and T47D). Moreover, the compensation was substantially blocked by 2μM tamoxifen. On the contrary, tamoxifen, alone, didn't affect the secretion of such cytokines mentioned above in vitro. Based on these findings, we tentatively concluded that some patients with ER positive breast cancers benefiting from anti-estrogen therapy may partially attributes to blocking monocyte differentiation into TAM, which destroyed the tumor microenvironment. These findings suggest the future possibility of using TAM as a novel therapeutic target in patients with anti-estrogen resistance and primary triple-negative breast cancers (TNBC) with no effectively therapeutic measures nowadays, which are defined by lack of estrogen receptor, progesterone receptor and ERBB2 gene amplification, representing approximately 16% of all breast cancers. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-04-26.

Inhibition of MAP Kinase Promotes the Recruitment of Corepressor SMRT by Tamoxifen-Bound Estrogen Receptor Alpha and Potentiates Tamoxifen Action in MCF-7 Cells.

[Effect of Mitogen-Activated Protein Kinase Signal Transduction in Non-Estrogen Antagonistic Mechanism of Tamoxifen].

Inhibition of Proliferation of Estrogen Receptor-Positive Mcf-7 Human Breast Cancer Cells by Tamoxifen Through C-Jun Transcription Factors

Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.

Tamoxifen activates Nrf2-dependent SQSTM1 transcription to promote endometrial hyperplasia.

Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways.

Tamoxifen promotes apoptosis and inhibits invasion in estrogen‑positive breast cancer MCF‑7 cells.

Mitogen-Activated Protein Kinase Phosphatase 1 Is Involved In Tamoxifen Resistance In Mcf7 Cells

[Expression of ER Alpha and SMRT in Apoptosis of Breast Cancer Cells Induced by Tamoxifen].

Mir-125a-3p Inhibits Er Alpha Transactivation And Overrides Tamoxifen Resistance By Targeting Cdk3 In Estrogen Receptor-Positive Breast Cancer

MEKK1 Activation of Human Estrogen Receptor Α and Stimulation of the Agonistic Activity of 4-Hydroxytamoxifen in Endometrial and Ovarian Cancer Cells

Combined MEK Inhibition and Tumor-Associated Macrophages Depletion Suppresses Tumor Growth in a Triple-Negative Breast Cancer Mouse Model

RSK-Mediated Non-canonical Activation of EphA2 by Tamoxifen

Studies on Resistant Induction of Breast Cancer Cell MCF-7 to Tamoxifen in Vitro

Mtdh Mediates Estrogen-Independent Growth and Tamoxifen Resistance by Down-Regulating Pten in Mcf-7 Breast Cancer Cells

MCAM/CD146 Promotes Tamoxifen Resistance in Breast Cancer Cells Through Induction of Epithelial–mesenchymal Transition, Decreased ERα Expression and AKT Activation

Sphingosine Kinase (sphk) Mediates Transactivation of the Epidermal Growth Factor Receptor (egfr) by Estrogen in Breast Cancer Cells

Identification of differentially expressed genes in human breast cancer cells induced by 4-hydroxyltamoxifen and elucidation of their pathophysiological relevance and mechanisms

Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells.

Abstract P6-04-26: Tamoxifen May Block Estrogen Induced Secretion of Certain Cytokines to Interrupt Tumor Associated Macrophage Infiltration in Breast Cancer

ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.